FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Journal of virology1992; 66(6); 3398-3408; doi: 10.1128/JVI.66.6.3398-3408.1992

Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus.

Abstract: We report here on a series of vaccine trials to evaluate the effectiveness of an inactivated equine infectious anemia virus (EIAV) whole-virus vaccine and of a subunit vaccine enriched in EIAV envelope glycoproteins. The inactivated vaccine protected 14 of 15 immunized ponies from infection after challenge with at least 10(5) 50% tissue culture-infective doses of the homologous prototype strain of EIAV. In contrast, it failed to prevent infection in any of 15 immunized ponies that were challenged with the heterologous PV strain. Levels of PV virus replication and the development of disease, however, were significantly reduced in 12 of the 15 ponies so challenged. The subunit vaccine prevented infection from homologous challenge in four of four ponies tested but failed to prevent infection in all four challenged with the PV strain. Two of the four subunit vaccinates had more severe symptoms of equine infectious anemia than nonimmunized ponies infected in parallel. Both vaccines stimulated EIAV-specific cell-mediated immunity. The in vitro lymphoproliferative response was shown to be mediated by T lymphocytes and appeared to be indistinguishable from that induced by EIAV infection. Significant differences were observed in the in vivo lymphocyte responses following challenge with the two virus strains. While peripheral blood mononuclear cells from the inactivated virus vaccinates were equally stimulated by both the prototype and PV strains, the subunit vaccinates challenged with PV exhibited lower levels of spontaneous proliferation and serine esterase activity. This diminished cellular response to PV was correlated with more severe clinical disease in the same ponies. These studies demonstrate for the first time that both an EIAV inactivated whole-virus vaccine and a viral envelope glycoprotein-based subunit vaccine can provide protection against rigorous challenge levels of homologous virus but are unable to protect against similar challenge levels of a heterologous virus. Moreover, the data demonstrate that protection can be achieved in the absence of detectable levels of virus-specific neutralizing antibody in the vaccine recipients at the time of virus challenge. While vaccine-induced virus-specific cell-mediated immune responses were detected, their role in conferring protection was not obvious. Nevertheless, protection from disease appeared to be correlated with the induction of high levels of serine esterase activity following challenge. A significant observation is that while the whole-virus vaccine was usually capable of preventing or markedly moderating disease in the PV-infected ponies, the subunit vaccine appeared to have a high potential to enhance the disease induced by PV infection.(ABSTRACT TRUNCATED AT 400 WORDS)
Get Full Text
Publication Date: 1992-06-11 PubMed ID: 1316455PubMed Central: PMC241120DOI: 10.1128/JVI.66.6.3398-3408.1992Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Clinical Trial
  • Comparative Study
  • Journal Article
  • Research Support
  • Non-U.S. Gov't
  • Research Support
  • U.S. Gov't
  • P.H.S.

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research investigates how effective inactivated and subunit vaccines are at preventing infection and disease caused by the equine infectious anemia virus (EIAV). The findings indicate that while these vaccines can protect against a homologous virus, they fail to protect against a heterologous virus.

Vaccine Trials

  • The study conducted a series of trials to test two vaccines: an inactivated equine infectious anemia virus (EIAV) whole-virus vaccine and a subunit vaccine, which is enriched in EIAV envelope glycoproteins. The objective was to evaluate their effectiveness in preventing infection and disease caused by EIAV.
  • For the inactivated vaccine, out of the 15 immunized ponies, 14 were protected from the homologous prototype strain of EIAV. Conversely, the same vaccine failed against the heterologous PV strain but was able to reduce its replication and development of the disease in 12 out of the 15 ponies.
  • The subunit vaccine protected against the homologous virus in all four tested ponies but failed against the PV strain. More alarmingly, two out of the four ponies had more severe symptoms than non-immunized ponies.

Immune Responses and Observations

  • Both vaccines were able to stimulate EIAV-specific cell-mediated immunity. In regards to lymph proliferative responses, the study showed that they were mediated by T-lymphocytes, which aligned with those induced by EIAV infection.
  • Significant differences emerged in the immune responses from in vivo lymphocytes in the two virus strains. Ponies vaccinated with the inactivated virus exhibited equal stimulation from both strains. However, those vaccinated with the subunit vaccine exhibited lower levels of spontaneous proliferation and serine esterase activity when infected with the PV strain.
  • These diminished cellular responses aligned with more severe symptoms of the equine infectious anemia, suggesting a correlation. The findings propose that protection against the virus correlated with high levels of serine esterase activity following a challenge.

Conclusion

  • The results suggest that despite each vaccine’s ability to protect against a homologous virus, they fall short in protecting against a heterologous virus. This failure occurred even in the absence of detectable levels of virus-specific neutralizing antibodies at the time of challenge.
  • Overall, while the whole-virus vaccine could usually prevent or significantly reduce disease in PV-infected ponies, the subunit vaccine appeared to potentially enhance the disease provoked by PV infection.

Cite This Article

APA
Issel CJ, Horohov DW, Lea DF, Adams WV, Hagius SD, McManus JM, Allison AC, Montelaro RC. (1992). Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus. J Virol, 66(6), 3398-3408. https://doi.org/10.1128/JVI.66.6.3398-3408.1992

Publication

Journal of virology
ISSN: 0022-538X
NlmUniqueID: 0113724
Country: United States
Language: English
Volume: 66
Issue: 6
Pages: 3398-3408

Researcher Affiliations

Issel, C J
  • Department of Veterinary Science, Louisiana Agricultural Experiment Station, Baton Rouge.
Horohov, D W
    Lea, D F
      Adams, W V
        Hagius, S D
          McManus, J M
            Allison, A C
              Montelaro, R C

                MeSH Terms

                • Animals
                • Antibody Formation
                • Cells, Cultured
                • Equine Infectious Anemia / immunology
                • Equine Infectious Anemia / prevention & control
                • Horses / immunology
                • Infectious Anemia Virus, Equine / immunology
                • Lymphocyte Activation
                • Vaccines / administration & dosage
                • Viral Envelope Proteins / immunology
                • Viral Vaccines / therapeutic use
                • Virion / immunology
                • Virus Replication

                Grant Funding

                • AI25850 / NIAID NIH HHS

                References

                This article includes 37 references
                1. Amborski GF, Jeffers G, Amborski RL, Issel CJ. Equine infectious anemia virus: development of a simple reproducible method for titrating infectivity of the cell-adapted strain.. Am J Vet Res 1979 Feb;40(2):302-4.
                  pubmed: 223479
                2. Shively MA, Banks KL, Greenlee A, Klevjer-Anderson P. Antigenic stimulation of T lymphocytes in chronic nononcogenic retrovirus infection: equine infectious anemia.. Infect Immun 1982 Apr;36(1):38-46.
                  pubmed: 6281191doi: 10.1128/iai.36.1.38-46.1982google scholar: lookup
                3. Kurth R, Binninger D, Ennen J, Denner J, Hartung S, Norley S. The quest for an AIDS vaccine: the state of the art and current challenges.. AIDS Res Hum Retroviruses 1991 May;7(5):425-33.
                  pubmed: 1873078doi: 10.1089/aid.1991.7.425google scholar: lookup
                4. Carlson JR, McGraw TP, Keddie E, Yee JL, Rosenthal A, Langlois AJ, Dickover R, Donovan R, Luciw PA, Jennings MB. Vaccine protection of rhesus macaques against simian immunodeficiency virus infection.. AIDS Res Hum Retroviruses 1990 Nov;6(11):1239-46.
                  pubmed: 2078406doi: 10.1089/aid.1990.6.1239google scholar: lookup
                5. Welsh RM, Nishioka WK, Antia R, Dundon PL. Mechanism of killing by virus-induced cytotoxic T lymphocytes elicited in vivo.. J Virol 1990 Aug;64(8):3726-33.
                  pubmed: 2115090doi: 10.1128/JVI.64.8.3726-3733.1990google scholar: lookup
                6. Rwambo PM, Issel CJ, Adams WV Jr, Hussain KA, Miller M, Montelaro RC. Equine infectious anemia virus (EIAV) humoral responses of recipient ponies and antigenic variation during persistent infection.. Arch Virol 1990;111(3-4):199-212.
                  pubmed: 2162160doi: 10.1007/BF01311054google scholar: lookup
                7. Homsy J, Meyer M, Levy JA. Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals.. J Virol 1990 Apr;64(4):1437-40.
                  pubmed: 2319642doi: 10.1128/JVI.64.4.1437-1440.1990google scholar: lookup
                8. Robinson WE Jr, Kawamura T, Gorny MK, Lake D, Xu JY, Matsumoto Y, Sugano T, Masuho Y, Mitchell WM, Hersh E. Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro.. Proc Natl Acad Sci U S A 1990 Apr;87(8):3185-9.
                  pubmed: 2326277doi: 10.1073/pnas.87.8.3185google scholar: lookup
                9. Nixon DF, Townsend AR, Elvin JG, Rizza CR, Gallwey J, McMichael AJ. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides.. Nature 1988 Dec 1;336(6198):484-7.
                  pubmed: 2461519doi: 10.1038/336484a0google scholar: lookup
                10. Montelaro R, Ball J, Rwambo P, Issel C. Antigenic variation during persistent lentivirus infections and its implications for vaccine development.. Adv Exp Med Biol 1989;251:251-72.
                  pubmed: 2481964doi: 10.1007/978-1-4757-2046-4_24google scholar: lookup
                11. Desrosiers RC, Wyand MS, Kodama T, Ringler DJ, Arthur LO, Sehgal PK, Letvin NL, King NW, Daniel MD. Vaccine protection against simian immunodeficiency virus infection.. Proc Natl Acad Sci U S A 1989 Aug;86(16):6353-7.
                  pubmed: 2548210doi: 10.1073/pnas.86.16.6353google scholar: lookup
                12. Jolly PE, Huso D, Hart G, Narayan O. Modulation of lentivirus replication by antibodies. Non-neutralizing antibodies to caprine arthritis-encephalitis virus enhance early stages of infection in macrophages, but do not cause increased production of virions.. J Gen Virol 1989 Aug;70 ( Pt 8):2221-6.
                  pubmed: 2549189doi: 10.1099/0022-1317-70-8-2221google scholar: lookup
                13. Payne SL, Fang FD, Liu CP, Dhruva BR, Rwambo P, Issel CJ, Montelaro RC. Antigenic variation and lentivirus persistence: variations in envelope gene sequences during EIAV infection resemble changes reported for sequential isolates of HIV.. Virology 1987 Dec;161(2):321-31.
                  pubmed: 2825406doi: 10.1016/0042-6822(87)90124-3google scholar: lookup
                14. Issel CJ, Rushlow K, Foil LD, Montelaro RC. A perspective on equine infectious anemia with an emphasis on vector transmission and genetic analysis.. Vet Microbiol 1988 Jul;17(3):251-86.
                  pubmed: 2847392doi: 10.1016/0378-1135(88)90069-7google scholar: lookup
                15. McGuire TC, Adams DS, Johnson GC, Klevjer-Anderson P, Barbee DD, Gorham JR. Acute arthritis in caprine arthritis-encephalitis virus challenge exposure of vaccinated or persistently infected goats.. Am J Vet Res 1986 Mar;47(3):537-40.
                  pubmed: 3008599
                16. Zarling JM, Morton W, Moran PA, McClure J, Kosowski SG, Hu SL. T-cell responses to human AIDS virus in macaques immunized with recombinant vaccinia viruses.. Nature 1986 Sep 25-Oct 1;323(6086):344-6.
                  pubmed: 3093891doi: 10.1038/323344a0google scholar: lookup
                17. Kono Y, Kobayashi K, Fukunaga Y. Antigenic drift of equine infectious anemia virus in chronically infected horses.. Arch Gesamte Virusforsch 1973;41(1):1-10.
                  pubmed: 4123810doi: 10.1007/BF01249923google scholar: lookup
                18. Malmquist WA, Barnett D, Becvar CS. Production of equine infectious anemia antigen in a persistently infected cell line.. Arch Gesamte Virusforsch 1973;42(4):361-70.
                  pubmed: 4358259doi: 10.1007/BF01250717google scholar: lookup
                19. Henson JB, McGuire TC. Equine infectious anemia.. Prog Med Virol 1974;18(0):143-59.
                  pubmed: 4371283
                20. Montelaro RC, Parekh B, Orrego A, Issel CJ. Antigenic variation during persistent infection by equine infectious anemia virus, a retrovirus.. J Biol Chem 1984 Aug 25;259(16):10539-44.
                  pubmed: 6206055
                21. Montelaro RC, West M, Issel CJ. Isolation of equine infectious anemia virus glycoproteins. Lectin affinity chromatography procedures for high avidity glycoproteins.. J Virol Methods 1983 Jun;6(6):337-46.
                  pubmed: 6309879doi: 10.1016/0166-0934(83)90056-3google scholar: lookup
                22. Issel CJ, Coggins L. Equine infectious anemia: current knowledge.. J Am Vet Med Assoc 1979 Apr 1;174(7):727-33.
                  pubmed: 218920
                23. Stott EJ. Anti-cell antibody in macaques.. Nature 1991 Oct 3;353(6343):393.
                  pubmed: 1815549doi: 10.1038/353393a0google scholar: lookup
                24. Murphey-Corb M, Montelaro RC, Miller MA, West M, Martin LN, Davison-Fairburn B, Ohkawa S, Baskin GB, Zhang JY, Miller GB. Efficacy of SIV/deltaB670 glycoprotein-enriched and glycoprotein-depleted subunit vaccines in protecting against infection and disease in rhesus monkeys.. AIDS 1991 Jun;5(6):655-62.
                  pubmed: 1883540doi: 10.1097/00002030-199106000-00003google scholar: lookup
                25. Montefiori DC, Robinson WE Jr, Hirsch VM, Modliszewski A, Mitchell WM, Johnson PR. Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques.. J Virol 1990 Jan;64(1):113-9.
                  pubmed: 2152808doi: 10.1128/JVI.64.1.113-119.1990google scholar: lookup
                26. Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, Wurm FM, Hershberg RD, Cobb EK, Eichberg JW. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.. Nature 1990 Jun 14;345(6276):622-5.
                  pubmed: 2190095doi: 10.1038/345622a0google scholar: lookup
                27. Knowles D Jr, Cheevers W, McGuire T, Stem T, Gorham J. Severity of arthritis is predicted by antibody response to gp135 in chronic infection with caprine arthritis-encephalitis virus.. J Virol 1990 May;64(5):2396-8.
                  pubmed: 2325206doi: 10.1128/JVI.64.5.2396-2398.1990google scholar: lookup
                28. Horohov DW, Crim JA, Smith PL, Siegel JP. IL-4 (B cell-stimulatory factor 1) regulates multiple aspects of influenza virus-specific cell-mediated immunity.. J Immunol 1988 Dec 15;141(12):4217-23.
                  pubmed: 2461987
                29. Gerencer M, Valpotić I, Jukić B, Tomasković M, Basić I. Qualitative analyses of cellular immune functions in equine infectious anemia show homology with AIDS.. Arch Virol 1989;104(3-4):249-57.
                  pubmed: 2523215doi: 10.1007/BF01315547google scholar: lookup
                30. Murphey-Corb M, Martin LN, Davison-Fairburn B, Montelaro RC, Miller M, West M, Ohkawa S, Baskin GB, Zhang JY, Putney SD. A formalin-inactivated whole SIV vaccine confers protection in macaques.. Science 1989 Dec 8;246(4935):1293-7.
                  pubmed: 2555923doi: 10.1126/science.2555923google scholar: lookup
                31. Perryman LE, O'Rourke KI, McGuire TC. Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection.. J Virol 1988 Aug;62(8):3073-6.
                  pubmed: 2839723doi: 10.1128/JVI.62.8.3073-3076.1988google scholar: lookup
                32. Pedersen NC, Johnson L, Birch D, Theilen GH. Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective.. Vet Immunol Immunopathol 1986 Feb;11(2):123-48.
                  pubmed: 3008409doi: 10.1016/0165-2427(86)90093-0google scholar: lookup
                33. O'Rourke K, Perryman LE, McGuire TC. Antiviral, anti-glycoprotein and neutralizing antibodies in foals with equine infectious anaemia virus.. J Gen Virol 1988 Mar;69 ( Pt 3):667-74.
                  pubmed: 3351480doi: 10.1099/0022-1317-69-3-667google scholar: lookup
                34. Kono Y, Kobayashi K, Fukunaga Y. Immunization of horses against equine infectious anemia (EIA) with an attenuated EIA virus.. Natl Inst Anim Health Q (Tokyo) 1970 Fall;10(3):113-22.
                  pubmed: 4320652
                35. Montelaro RC, Lohrey N, Parekh B, Blakeney EW, Issel CJ. Isolation and comparative biochemical properties of the major internal polypeptides of equine infectious anemia virus.. J Virol 1982 Jun;42(3):1029-38.
                  pubmed: 6178843doi: 10.1128/JVI.42.3.1029-1038.1982google scholar: lookup
                36. Issel CJ, Foil LD. Studies on equine infectious anemia virus transmission by insects.. J Am Vet Med Assoc 1984 Feb 1;184(3):293-7.
                  pubmed: 6321420
                37. Rwambo PM, Issel CJ, Hussain KA, Montelaro RC. In vitro isolation of a neutralization escape mutant of equine infectious anemia virus (EIAV).. Arch Virol 1990;111(3-4):275-80.
                  pubmed: 1693846doi: 10.1007/BF01311062google scholar: lookup

                Citations

                This article has been cited 36 times.
                1. Ishak J, Unsunnidhal L, Martien R, Kusumawati A. In Vitro Evaluation of Chitosan-DNA Plasmid Complex Encoding Jembrana Disease Virus Env-TM Protein as a Vaccine Candidate. J Vet Res 2019 Mar;63(1):7-16.
                  doi: 10.2478/jvetres-2019-0018pubmed: 30989130google scholar: lookup
                2. Craigo JK, Ezzelarab C, Cook SJ, Liu C, Horohov D, Issel CJ, Montelaro RC. Protective efficacy of centralized and polyvalent envelope immunogens in an attenuated equine lentivirus vaccine. PLoS Pathog 2015 Jan;11(1):e1004610.
                  doi: 10.1371/journal.ppat.1004610pubmed: 25569288google scholar: lookup
                3. Craigo JK, Montelaro RC. Lessons in AIDS vaccine development learned from studies of equine infectious, anemia virus infection and immunity. Viruses 2013 Dec 2;5(12):2963-76.
                  doi: 10.3390/v5122963pubmed: 24316675google scholar: lookup
                4. Craigo JK, Ezzelarab C, Cook SJ, Chong L, Horohov D, Issel CJ, Montelaro RC. Envelope determinants of equine lentiviral vaccine protection. PLoS One 2013;8(6):e66093.
                  doi: 10.1371/journal.pone.0066093pubmed: 23785473google scholar: lookup
                5. Meng Q, Lin Y, Ma J, Ma Y, Zhao L, Li S, Yang K, Zhou J, Shen R, Zhang X, Shao Y. A pilot study comparing the development of EIAV Env-specific antibodies induced by DNA/recombinant vaccinia-vectored vaccines and an attenuated Chinese EIAV vaccine. Viral Immunol 2012 Dec;25(6):477-84.
                  doi: 10.1089/vim.2012.0014pubmed: 23171359google scholar: lookup
                6. Craigo JK, Barnes S, Cook SJ, Issel CJ, Montelaro RC. Divergence, not diversity of an attenuated equine lentivirus vaccine strain correlates with protection from disease. Vaccine 2010 Nov 29;28(51):8095-104.
                  doi: 10.1016/j.vaccine.2010.10.003pubmed: 20955830google scholar: lookup
                7. Craigo JK, Barnes S, Zhang B, Cook SJ, Howe L, Issel CJ, Montelaro RC. An EIAV field isolate reveals much higher levels of subtype variability than currently reported for the equine lentivirus family. Retrovirology 2009 Oct 20;6:95.
                  doi: 10.1186/1742-4690-6-95pubmed: 19843328google scholar: lookup
                8. Huisman W, Martina BE, Rimmelzwaan GF, Gruters RA, Osterhaus AD. Vaccine-induced enhancement of viral infections. Vaccine 2009 Jan 22;27(4):505-12.
                  doi: 10.1016/j.vaccine.2008.10.087pubmed: 19022319google scholar: lookup
                9. van der Kuyl AC, Cornelissen M. Identifying HIV-1 dual infections. Retrovirology 2007 Sep 24;4:67.
                  doi: 10.1186/1742-4690-4-67pubmed: 17892568google scholar: lookup
                10. Craigo JK, Zhang B, Barnes S, Tagmyer TL, Cook SJ, Issel CJ, Montelaro RC. Envelope variation as a primary determinant of lentiviral vaccine efficacy. Proc Natl Acad Sci U S A 2007 Sep 18;104(38):15105-10.
                  doi: 10.1073/pnas.0706449104pubmed: 17846425google scholar: lookup
                11. Crooks ET, Moore PL, Franti M, Cayanan CS, Zhu P, Jiang P, de Vries RP, Wiley C, Zharkikh I, Schülke N, Roux KH, Montefiori DC, Burton DR, Binley JM. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 2007 Sep 30;366(2):245-62.
                  doi: 10.1016/j.virol.2007.04.033pubmed: 17580087google scholar: lookup
                12. Craigo JK, Durkin S, Sturgeon TJ, Tagmyer T, Cook SJ, Issel CJ, Montelaro RC. Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines. Vaccine 2007 Jan 15;25(5):834-45.
                  doi: 10.1016/j.vaccine.2006.09.040pubmed: 17023099google scholar: lookup
                13. Fraser DG, Leib SR, Zhang BS, Mealey RH, Brown WC, McGuire TC. Lymphocyte proliferation responses induced to broadly reactive Th peptides did not protect against equine infectious anemia virus challenge. Clin Diagn Lab Immunol 2005 Aug;12(8):983-93.
                  doi: 10.1128/CDLI.12.8.983-993.2005pubmed: 16085917google scholar: lookup
                14. Poon B, Hsu JF, Gudeman V, Chen IS, Grovit-Ferbas K. Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses. J Virol 2005 Aug;79(16):10210-7.
                  doi: 10.1128/JVI.79.16.10210-10217.2005pubmed: 16051814google scholar: lookup
                15. Poon B, Safrit JT, McClure H, Kitchen C, Hsu JF, Gudeman V, Petropoulos C, Wrin T, Chen IS, Grovit-Ferbas K. Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1. J Virol 2005 Apr;79(8):4927-35.
                  doi: 10.1128/JVI.79.8.4927-4935.2005pubmed: 15795278google scholar: lookup
                16. Craigo JK, Li F, Steckbeck JD, Durkin S, Howe L, Cook SJ, Issel C, Montelaro RC. Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy. J Virol 2005 Mar;79(5):2666-77.
                  doi: 10.1128/JVI.79.5.2666-2677.2005pubmed: 15708986google scholar: lookup
                17. Jin S, Issel CJ, Montelaro RC. Serological method using recombinant S2 protein to differentiate equine infectious anemia virus (EIAV)-infected and EIAV-vaccinated horses. Clin Diagn Lab Immunol 2004 Nov;11(6):1120-9.
                  doi: 10.1128/CDLI.11.6.1120-1129.2004pubmed: 15539516google scholar: lookup
                18. Chung C, Mealey RH, McGuire TC. CTL from EIAV carrier horses with diverse MHC class I alleles recognize epitope clusters in Gag matrix and capsid proteins. Virology 2004 Sep 15;327(1):144-54.
                  doi: 10.1016/j.virol.2004.06.035pubmed: 15327905google scholar: lookup
                19. Gould SJ, Booth AM, Hildreth JE. The Trojan exosome hypothesis. Proc Natl Acad Sci U S A 2003 Sep 16;100(19):10592-7.
                  doi: 10.1073/pnas.1831413100pubmed: 12947040google scholar: lookup
                20. Li F, Craigo JK, Howe L, Steckbeck JD, Cook S, Issel C, Montelaro RC. A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses. J Virol 2003 Jul;77(13):7244-53.
                  doi: 10.1128/jvi.77.13.7244-7253.2003pubmed: 12805423google scholar: lookup
                21. Fraser DG, Oaks JL, Brown WC, McGuire TC. Identification of broadly recognized, T helper 1 lymphocyte epitopes in an equine lentivirus. Immunology 2002 Mar;105(3):295-305.
                  doi: 10.1046/j.0019-2805.2001.01370.xpubmed: 11918691google scholar: lookup
                22. Hammond SA, Li F, McKeon BM Sr, Cook SJ, Issel CJ, Montelaro RC. Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus. J Virol 2000 Jul;74(13):5968-81.
                  doi: 10.1128/jvi.74.13.5968-5981.2000pubmed: 10846078google scholar: lookup
                23. Grovit-Ferbas K, Hsu JF, Ferbas J, Gudeman V, Chen IS. Enhanced binding of antibodies to neutralization epitopes following thermal and chemical inactivation of human immunodeficiency virus type 1. J Virol 2000 Jul;74(13):5802-9.
                  doi: 10.1128/jvi.74.13.5802-5809.2000pubmed: 10846059google scholar: lookup
                24. Lonning SM, Zhang W, McGuire TC. Gag protein epitopes recognized by CD4(+) T-helper lymphocytes from equine infectious anemia virus-infected carrier horses. J Virol 1999 May;73(5):4257-65.
                  doi: 10.1128/JVI.73.5.4257-4265.1999pubmed: 10196322google scholar: lookup
                25. Zhang W, Lonning SM, McGuire TC. Gag protein epitopes recognized by ELA-A-restricted cytotoxic T lymphocytes from horses with long-term equine infectious anemia virus infection. J Virol 1998 Dec;72(12):9612-20.
                  doi: 10.1128/JVI.72.12.9612-9620.1998pubmed: 9811694google scholar: lookup
                26. Connor RI, Korber BT, Graham BS, Hahn BH, Ho DD, Walker BD, Neumann AU, Vermund SH, Mestecky J, Jackson S, Fenamore E, Cao Y, Gao F, Kalams S, Kunstman KJ, McDonald D, McWilliams N, Trkola A, Moore JP, Wolinsky SM. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol 1998 Feb;72(2):1552-76.
                  doi: 10.1128/JVI.72.2.1552-1576.1998pubmed: 9445059google scholar: lookup
                27. Cook RF, Leroux C, Cook SJ, Berger SL, Lichtenstein DL, Ghabrial NN, Montelaro RC, Issel CJ. Development and characterization of an in vivo pathogenic molecular clone of equine infectious anemia virus. J Virol 1998 Feb;72(2):1383-93.
                  doi: 10.1128/JVI.72.2.1383-1393.1998pubmed: 9445039google scholar: lookup
                28. Richardson J, Moraillon A, Baud S, Cuisinier AM, Sonigo P, Pancino G. Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope. J Virol 1997 Dec;71(12):9640-9.
                  doi: 10.1128/JVI.71.12.9640-9649.1997pubmed: 9371628google scholar: lookup
                29. Hammond SA, Cook SJ, Lichtenstein DL, Issel CJ, Montelaro RC. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J Virol 1997 May;71(5):3840-52.
                  doi: 10.1128/JVI.71.5.3840-3852.1997pubmed: 9094660google scholar: lookup
                30. Langemeier JL, Cook SJ, Cook RF, Rushlow KE, Montelaro RC, Issel CJ. Detection of equine infectious anemia viral RNA in plasma samples from recently infected and long-term inapparent carrier animals by PCR. J Clin Microbiol 1996 Jun;34(6):1481-7.
                  doi: 10.1128/jcm.34.6.1481-1487.1996pubmed: 8735102google scholar: lookup
                31. Levy JA. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 1993 Mar;57(1):183-289.
                  doi: 10.1128/mr.57.1.183-289.1993pubmed: 8464405google scholar: lookup
                32. Sellon DC. Equine infectious anemia. Vet Clin North Am Equine Pract 1993 Aug;9(2):321-36.
                  doi: 10.1016/s0749-0739(17)30399-1pubmed: 8395326google scholar: lookup
                33. Tartaglia J, Jarrett O, Neil JC, Desmettre P, Paoletti E. Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J Virol 1993 Apr;67(4):2370-5.
                  doi: 10.1128/JVI.67.4.2370-2375.1993pubmed: 8383248google scholar: lookup
                34. McGuire TC, Tumas DB, Byrne KM, Hines MT, Leib SR, Brassfield AL, O'Rourke KI, Perryman LE. Major histocompatibility complex-restricted CD8+ cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins. J Virol 1994 Mar;68(3):1459-67.
                  doi: 10.1128/JVI.68.3.1459-1467.1994pubmed: 8107209google scholar: lookup
                35. Sellon DC, Fuller FJ, McGuire TC. The immunopathogenesis of equine infectious anemia virus. Virus Res 1994 May;32(2):111-38.
                  doi: 10.1016/0168-1702(94)90038-8pubmed: 8067050google scholar: lookup
                36. Cook RF, Berger SL, Rushlow KE, McManus JM, Cook SJ, Harrold S, Raabe ML, Montelaro RC, Issel CJ. Enhanced sensitivity to neutralizing antibodies in a variant of equine infectious anemia virus is linked to amino acid substitutions in the surface unit envelope glycoprotein. J Virol 1995 Mar;69(3):1493-9.
                  doi: 10.1128/JVI.69.3.1493-1499.1995pubmed: 7853482google scholar: lookup
                Subscribe to our newsletter
                Join 99,850 horse owners like you who receive our email updates on horse health and nutrition.